Overview

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to explore the clinical and immunological efficacy of Telitacicept and low dose IL-2 on systemic lupus erythematosus.
Phase:
Phase 3
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Aldesleukin
Interleukin-2